Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

WCLC 2021 | ALK mutations in ctDNA predict responses to next generation ALK TKIs in NSCLC

Laura Mezquita, Hospital Clinic Barcelona, Barcelona, Spain, shares the findings of the ARIA study: an assessment of the activity of next-generation ALK tyrosine kinase inhibitors (TKIs) based of the presence of ALK resistance mutations (ALKm) in ctDNA. ALK-positive advanced non-small cell lung cancer (NSCLC) patients with prior ALK-TKI therapy were identified and a liquid biopsy was conducted prior to brigatinib or lorlatinib treatment. ALKm were detected in 28% of the population, where G1202R was the most common. Lorlatinib was shown to have more activity in ALKm patients compared with brigatinib, with superior response rates and progression free survival. The findings suggest ctDNA could act as a biomarker to guide sequential treatment choices but larger trials are needed. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.

Disclosures

Research grants/funding: Bristol Myers Squibb, Boehringer Ingelheim, Amgen
Advisory/Consultancy: Roche Diagnostics, Takeda
Honoraria: Bristol Myers Squibb, Tecnofarma, Roche
Travel/Accommodation/Expenses: Roche
Non-remunerated activity: AstraZeneca

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.